WaveMan
WaveMan · Company
BOLD · Boundless Bio, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

BOLD Boundless Bio (BOLD) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001782303
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
23
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $33.0K priced

What the filings say about BOLD

Insiders, 180 days
+$1.8M net bought
1 buyer · 3 sellers · 0% of sales under a 10b5-1 plan

Boundless Bio insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Boundless Bio, Inc. insiders bought a net $1.8M of stock across 40 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
TANG KEVIN
BUY
2026-10-26 SEC
9,606
$22.9K
n/a
Context
  • 29 earlier Form 4 trades (code P or S) here by this insider (28 buys, 1 sale), the last on Oct 23, 2026.
  • +3.8% median (+1.9% mean) 90-day return after 18 previous buys.
  • The trade is 0.3% of the 3,011,749 shares held after it.
  • No other insider bought within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider TANG KEVIN bought about $22.9K of BOLD on Oct 26, 2026; 23 funds added in the latest 13F quarter.
TANG KEVIN
BUY
2026-10-26 SECtraded 2026-10-23
6,234
$14.8K
n/a
Context
  • 28 earlier Form 4 trades (code P or S) here by this insider (27 buys, 1 sale), the last on Oct 22, 2026.
  • +3.8% median (+1.9% mean) 90-day return after 18 previous buys.
  • The trade is 0.2% of the 3,002,143 shares held after it.
  • No other insider bought within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider TANG KEVIN bought about $14.8K of BOLD on Oct 23, 2026; 23 funds added in the latest 13F quarter.
TANG KEVIN
BUY
2026-10-26 SECtraded 2026-10-22
5,800
$13.9K
n/a
Context
  • 27 earlier Form 4 trades (code P or S) here by this insider (26 buys, 1 sale), the last on Oct 20, 2026.
  • +3.8% median (+1.9% mean) 90-day return after 18 previous buys.
  • The trade is 0.2% of the 2,995,909 shares held after it.
  • No other insider bought within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider TANG KEVIN bought about $13.9K of BOLD on Oct 22, 2026; 23 funds added in the latest 13F quarter.
TANG KEVIN
BUY
2026-10-20 SEC
220
$521
-1.2%
Context
  • 26 earlier Form 4 trades (code P or S) here by this insider (25 buys, 1 sale), the last on Oct 19, 2026.
  • +3.8% median (+1.9% mean) 90-day return after 18 previous buys.
  • The trade is 0.0% of the 2,990,109 shares held after it.
  • No other insider bought within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider TANG KEVIN bought about $521 of BOLD on Oct 20, 2026; 23 funds added in the latest 13F quarter.
TANG KEVIN
BUY
2026-10-20 SECtraded 2026-10-19
12,790
$29.9K
-1.2%
Context
  • 24 earlier Form 4 trades (code P or S) here by this insider (23 buys, 1 sale), the last on Oct 16, 2026.
  • +3.8% median (+1.9% mean) 90-day return after 18 previous buys.
  • The trade is 0.4% of the 2,971,610 shares held after it.
  • No other insider bought within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider TANG KEVIN bought about $29.9K of BOLD on Oct 19, 2026; 23 funds added in the latest 13F quarter.
40 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 35 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$1.8M over 180 days
+$346.9K over 90 days · +$1.8M of it by a 10%+ holder
more than 91% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
23 funds bought in last quarter
below 66% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
4.9% of the float short (float per yahoo 2026-10-26) · 4.2 days to cover · settled 2026-09-30
below 57% of Pharma & Biotech
What changed in the last 30 days
Oct 26Insider TANG KEVIN bought $401.2K (7 trades, Oct 16 to Oct 26)

Watch BOLD

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+70.9%12M
-26%+21%+67%+113%2025-102025-122026-022026-042026-062026-082026-10 2026-06-25 · TANG KEVIN bought $361.8K2026-10-16 · TANG KEVIN bought $276.6K2026-06-26 · TANG KEVIN bought $191.4K2026-07-01 · TANG KEVIN bought $178.3K2026-06-29 · TANG KEVIN bought $158.0K2026-07-13 · TANG KEVIN bought $116.7K2026-07-14 · TANG KEVIN bought $106.6K2026-07-10 · TANG KEVIN bought $105.4K2026-07-06 · TANG KEVIN bought $67.4K2026-06-30 · TANG KEVIN bought $65.9K2026-08-26 · TANG KEVIN sold $54.4K2026-07-16 · TANG KEVIN bought $45.1K2026-10-19 · TANG KEVIN bought $42.6K2026-07-01 · ARCH Venture Fund IX, L.P. sold $39.8K2026-07-01 · CRANDELL KEITH sold $39.8K2026-07-07 · TANG KEVIN bought $39.2K2026-07-08 · TANG KEVIN bought $35.3K2026-10-19 · TANG KEVIN bought $29.9K2026-07-02 · TANG KEVIN bought $24.5K2026-10-26 · TANG KEVIN bought $22.9K2026-10-23 · TANG KEVIN bought $14.8K2026-10-22 · TANG KEVIN bought $13.9K2026-07-21 · TANG KEVIN bought $7.3K2026-07-20 · TANG KEVIN bought $4.0K2026-07-15 · TANG KEVIN bought $3.9K2026-06-29 · TANG KEVIN bought $1.9K2026-06-25 · TANG KEVIN bought $1.3K2026-07-17 · TANG KEVIN bought $6472026-10-20 · TANG KEVIN bought $5212026-06-26 · TANG KEVIN bought $3402026-06-30 · TANG KEVIN bought $2502026-07-09 · TANG KEVIN bought $17
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BOLD: institutional holders (13F)

13F holdings, latest reported quarter
ARCH Venture Management, LLC
2,694,095 sh
$6.7M
FMR LLC
2,581,055 sh
$6.5M
TANG CAPITAL MANAGEMENT LLC
2,559,875 sh
$6.4M
ADAR1 Capital Management, LLC
1,968,216 sh
$4.9M
Cormorant Asset Management, LP
1,000,000 sh
$2.5M

Congress trades in BOLD

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BOLD planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

BOLD mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$193.8K position · as of 2026-06-30
0.2%
Ultra-Small Company Market Fund
$126.2K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$147.1K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$10.2K position · as of 2026-06-30
0.0%
Fidelity Growth Company Fund
$1.3M position · as of 2026-05-31
0.0%
Fidelity Series Growth Company Fund
$294.1K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $1.8M bought by insiders over 180 days, 23 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

BOLD financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$56.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-67.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-50.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-57.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-103.5%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Operating income-$63.6M-$73.3M-$54.8M
Net income-$58.2M-$65.4M-$49.4M
EPS (diluted)-2.60-3.85-40.65
Operating cash flow-$46.7M-$60.8M-$46.9M
Cash$17.9M$26.6M$23.7M
SEC XBRL, fiscal years, as known on 2026-10-28

BOLD Stock Sonar score 4/7 axes

Find similar shapesCompare

BOLD ranks highest on insider conviction (74th percentile) and risk and compliance (59th), and lowest on institutional and government (34th), among Pharma & Biotech peers.

Profitability
43
Inputs
  • Return on equity-67.9% · 44 pct, sector of 545
  • Return on assets-50.6% · 44 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-57.6% · 43 pct, sector of 576
Insider conviction
74
Inputs
  • Net Form 4 buying (codes P and S), 180d$1.8M · 91 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
34
Inputs
  • Funds adding, latest quarter23 · 34 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
59
Inputs
  • Short interest, % of float+4.9% · 59 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

BOLD filings, in plain words

Are Boundless Bio insiders buying or selling BOLD?

In the 180 days to 2026-10-28, Boundless Bio insiders were net buyers, a net $1.8M: $1.9M of purchases and $134.0K of sales reported on Form 4, by 1 buyer and 3 sellers.

Read the full summary

In the 180 days to 2026-10-28, Boundless Bio insiders were net buyers of BOLD, a net $1.8M across purchases and sales reported on Form 4 by 1 buyer and 3 sellers. Most of that figure, $1.8M, came from a holder of 10% or more rather than an officer or director. Purchases outweighed sales more than tenfold by value. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies